Shares of Wetherby-based life sciences company Avacta Group fell more than 25% after it carried out a heavily discounted share placing. The company said it successfully…

Wetherby-based life sciences company Avacta Group announced the appointment of experienced dealmaker Simon Bennett as chief business officer of its Therapeutics Division.  “Simon has over 26…

Wetherby-based life sciences company Avacta Group announced it has acquired Belgium-based Coris Bioconcept SRL for an upfront cash consideration of £7.4 million with an earnout…

Wetherby-based life sciences company Avacta Group said its reported group revenues for the year ended December 31, 2022, increased to £9.65 million compared from £2.94…

Shares of Wetherby-based life sciences company Avacta Group rose about 13% after it announced that its tumour targeted therapy AVA6000 “continues to show a very favourable…

Wetherby-based clinical stage oncology drug company Avacta Group said it agreed to acquire Kent-based Launch Diagnostics Holdings Ltd. for up to £37 million and that it…

Wetherby-based clinical stage oncology drug company Avacta Group plc announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the…

Wetherby-based clinical stage oncology drug company Avacta Group plc announced that AffyXell, its joint venture with Daewoong Pharmaceuticals has successfully completed a funding round to advance…

Shares of Wetherby-based clinical stage oncology drug company Avacta Group plc rose 11% on Wednesday after it announced that the first-in-human Phase I trial of…

Shares of Wetherby-based diagnostics company Avacta Group plc rose 12% on Friday after it announced that AffyXell Therapeutic, a joint venture between Avacta and Daewoong Pharmaceutical, entered into…

Wetherby-based diagnostics company Avacta Group plc announced that Vimian Group AB has acquired Avacta’s veterinary division Avacta Animal Health for up to £2.3 million. “Avacta Animal Health…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 12% on Thursday after it reported that “the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 14% on Tuesday after it announced its next pre|CISION drug candidate, AVA3996, has been selected for…

Shares of Wetherby-based diagnostics company Avacta Group plc fell about 30% on Monday after it announced it has paused sales of its Covid-19 AffiDX antigen lateral flow…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 17% on Wednesday after it said its AffiDX SARS-CoV-2 antigen lateral flow test has received a…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 4% on Monday after it announced US Food and Drug Administration (FDA) approval for its Investigational New…

Shares of Wetherby-based diagnostics company Avacta Group plc fell about 9% on Tuesday after it said it has suspended further sales of its AffiDX SARS-CoV-2 Lateral…

Shares of Wetherby-based cancer therapies and diagnostics company Avacta Group plc rose about 5% after it announced that a pre-clinical development milestone has been achieved in its…

Shares of Wetherby-based diagnostics company Avacta Group plc rose about 5% on Tuesday after it announced that a study has shown that its AffiDX antigen lateral…

Shares of Wetherby-based diagnostics company Avacta Group plc fell about 12% on Monday despite the firm announcing it entered into a non-exclusive distribution agreement with Calibre…

Shares of Wetherby-based diagnostics company Avacta Group plc rose another 18% on Friday after it announce that it has received notice of registration of its AffiDX…

Shares of Wetherby-based cancer therapies and diagnostics company Avacta Group plc rose another 8% on Tuesday after it announced positive data from the clinical validation…

Shares of Wetherby-based cancer therapies and diagnostics company Avacta Group plc rose another 8% on Tuesday after it announced it entered into a global distribution agreement…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 9% on Monday after it announced its AffiDX SARS-CoV-2 rapid antigen lateral flow test “detects the…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 18% on Tuesday after the firm said it has received the first data for its…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose about 7% on Monday after it said it entered into a commercial partnership with Mologic Ltd “to…

Wetherby-based biotherapeutics company Avacta Group plc said on Monday that AffyXell Therapeutics, its joint venture with Daewoong Pharmaceutical, has closed a Series A venture capital investment…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose 3% on Thursday after it said it has entered into a license agreement with Point Biopharma…

Wetherby-based biotherapeutics company Avacta Group plc announced on Monday “significant progress” in the development of a “highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose 12% on Thursday after the company published an update on its collaboration with the University of Glasgow…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 8% on Thursday after it said it raised £48 million by selling new shares in the…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 30% on Friday after it published a stock market statement on a “very exciting development” in…

Shares of Wetherby-based biotherapeutics company Avacta Group plc rose another 14% on Friday after it announced it entered a collaboration with Massachusetts-based Adeptrix to develop…